BWXT and Bayer to focus on therapeutic radionuclides

By staff writers

September 16, 2021 -- BWXT Medical and Bayer have entered an agreement to ramp up their supply of actinium-225 (Ac-225) as both companies seek to broaden commercialization strategies for targeted radionuclide therapies.

Processing and manufacturing will be conducted at BWXT facilities, while the complete terms of the commercial agreement will be finalized at a later date, the companies said.

Ac-225 is a radioisotope used in targeted alpha therapies, an emerging class of radionuclide therapy for various tumors with high unmet medical needs. The radionuclide delivers alpha radiation directly to tumors.

The agreement anticipates significant growth in the targeted radionuclide therapy market, said BWX Technologies, BWXT Medical's parent company.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking